UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~December~~January 320, ~~2025~~2026

INTERPACE BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware

000-24249

22-2919486

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Waterview Plaza, Suite 310, 2001 Route 46

Parsippany, NJ 07054

(Address, including zip code, of Principal Executive Offices)

(855) 776-6419

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On ~~December~~January 320, ~~2025~~2026, Interpace Biosciences, Inc. (the “Company”) issued a press release (the “Press Release”) announcing preliminary ~~that~~and itunaudited ~~has~~revenue ~~fully~~for ~~repaid~~the ~~its~~year ~~outstanding~~ended ~~term~~December ~~loan~~31, ~~facility with~~2025, ~~BroadOak~~along ~~Capital~~with ~~Partners~~certain ~~prior~~other toinformation including the ~~facility’s~~conversion of ~~maturity~~preferred ~~date~~stock described below. AThe ~~copy~~full text of the ~~press~~Press ~~release~~Release is ~~filed~~furnished as Exhibit 99.1 ~~hereto and~~attached ~~incorporated herein by reference~~hereto.

Item 7.01 Regulation FD Disclosure.

In the Press Release, the Company also announced that all of the outstanding shares of its Series C Preferred Stock were converted into shares of its common stock.

The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated ~~December~~January 320, ~~2025~~2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTERPACE BIOSCIENCES, INC.

	By:	/s/ Thomas W. Burnell
	Name:	Thomas W. Burnell
	Title:	President and Chief Executive Officer

Date: ~~December~~January 320, ~~2025~~2026

Filing Compare · INTERPACE BIOSCIENCES, INC.